The Medical Letter on Drugs and Therapeutics
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved selexipag (Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram), an oral prostacyclin analog, was approved earlier for this indication.

STANDARD TREATMENT — Monotherapy with an oral drug is usually recommended for initial treatment of PAH (WHO functional class II or III). Drugs approved by the FDA for this indication include phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists, and a guanylate cyclase stimulator (see Table 2). Patients with more advanced disease may be treated with a prostacyclin (epoprostenol, iloprost, or treprostinil). Current US guidelines recommend treatment with two or more classes of drugs only when the response is inadequate or the patient deteriorates on monotherapy, but a recent study found that first-line ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Selexipag (Uptravi) for Pulmonary Arterial Hypertension
Article code: 1488b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian